Vanc Biotechnology

Alzheimer's Early Detection and its Combination Drug

will help you get better and stay healthier.

1. Combination Alzheimer's disease (AD) drug (NV909AD) targeting both β-amyloid 

protein and neuroinflammation, supported by the combined β-amyloid protein 

and neuroinflammation hypothesis. 

β-Amyloid protein and neuroinflammation are the hallmarks of AD pathogenesis in the brain. 

NV909AD is the first combination AD drug targeting both β-amyloid protein

and neuroinflammation. NV909AD would increase the drug effectiveness to slow down cognitive

decline of Alzheimer’s patients, compared with mono β-amyloid antibody-based drug such as

Biogen's lecanemab and Eli lilly's donanemab. 

For neuroinflammatory drug we have a potential candidate of Turmeric Curcumin, which is derived

from the rhizome of the Curcuma longa. Specially it reduces incidence rate of Alzheimer-related

dementia by 4.4 time in the Indian of people consuming turmeric curcumin. So the abundant use of

turmeric-rich diet is thought to improve brain memory and prevent cognitive decline.

Curcumin is loaded to the Nano Particles (NP) using nanotechnology. This unique turmeric curcumin

NP gives significantly increased anti-inflammatory and anti-oxidant effect, thus enhancing its

efficacy because of its bioavailability and biostability. Our unique curcumin NP-containing AD drug can cross blood brain barrier, as seen in the oral curcumin's test in the small elderly group.

Combination AD drug, NV909AD,  would be a potential strategy to overcome the

limited effectiveness of anti-Aβ antibody therapeutic drug.

The company plans to test its efficacy and safety in an attempt to increase clinical trial 

outcome. 

2. Cancer immunotherapeutic drug (NV901C) targeting abnormal extracellular matrix (ECM)-associated breast cancer antigen (ECM-BrCA) for the treatment of cancer patients with breast cancer.

ECM-BrCA targeting therapeutic strategies are designed to neutralize abnormal ECM-BrCA in an effort to block tumor growth and metastasis in breast cancer. These strategies include ECM-BrCA neutralizing antibody, treatment dose, method, safety, efficacy, etc.

                         Early Diagnosis of Alzheimer's Disease                           

( Bioassay to measure β-amyloid protein autoantibody and 

total antioxidant capacity (TAC) in blood serum)

Testing service is now available.

(At-Home blood collection kit with lancet and shipping are free.)

Please inquire Request Form through Contact US,

Or fill Request Form through Ordering.

About Us

Vanc Biotechnology is committed to the research and development of diagnosis and drugs for cancer, 

alzheimer's diseases.

 

Our commitment is to develop the preventive screening test from human blood serum or plasma for 

the early detection and diagnosis of human cancers, and also alzheimer's diseases. We believe that our efforts will contribute to the better and healthier life.

 

Along this line, Vanc Biotechnology has been participated in the development of new serum biomarkers 

for early cancers and Alzheimer's diseases.